Cargando…

Impact of headache frequency and preventive medication failure on quality of life, functioning, and costs among individuals with migraine across several European countries: need for effective preventive treatment

BACKGROUND: Data are limited regarding the combined impact of headache frequency and failure of preventive medication (efficacy and/or tolerability) on the humanistic/economic burden of migraine. METHODS: A retrospective, cross-sectional analysis of 2020 National Health and Wellness Survey (NHWS) da...

Descripción completa

Detalles Bibliográficos
Autores principales:	Buse, Dawn C., Pozo-Rosich, Patricia, Dupont-Benjamin, Laure, Balkaran, Bridget L., Lee, Lulu, Jauregui, Adam, Gandhi, Pranav, Parikh, Mousam, Reuter, Uwe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Milan 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10464178/ https://www.ncbi.nlm.nih.gov/pubmed/37612633 http://dx.doi.org/10.1186/s10194-023-01655-5

Ejemplares similares

European headache federation consensus on the definition of resistant and refractory migraine: Developed with the endorsement of the European Migraine & Headache Alliance (EMHA)
por: Sacco, Simona, et al.
Publicado: (2020)

Burden and attitude to resistant and refractory migraine: a survey from the European Headache Federation with the endorsement of the European Migraine & Headache Alliance
por: Sacco, Simona, et al.
Publicado: (2021)

Non-invasive neuromodulation for migraine and cluster headache: a systematic review of clinical trials
por: Reuter, Uwe, et al.
Publicado: (2019)

Measuring the impact of migraine for evaluating outcomes of preventive treatments for migraine headaches
por: Mannix, Sally, et al.
Publicado: (2016)

Burden of Illness Among People with Migraine and ≥ 4 Monthly Headache Days While Using Acute and/or Preventive Prescription Medications for Migraine
por: Buse, Dawn C., et al.
Publicado: (2020)

Burden of Migraine in Patients With Preventive Treatment Failure Attending European Headache Specialist Centers: Real-World Evidence From the BECOME Study
por: Pozo-Rosich, Patricia, et al.
Publicado: (2021)

Influence of headache pain intensity and frequency on migraine-related disability in chronic migraine patients treated with OnabotulinumtoxinA
por: Torres-Ferrus, Marta, et al.
Publicado: (2020)

Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation
por: Bendtsen, Lars, et al.
Publicado: (2018)

European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention
por: Sacco, Simona, et al.
Publicado: (2019)

Effect of Atogepant for Preventive Migraine Treatment on Patient-Reported Outcomes in the Randomized, Double-blind, Phase 3 ADVANCE Trial
por: Lipton, Richard B., et al.
Publicado: (2023)

Correction to: European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention
por: Sacco, Simona, et al.
Publicado: (2019)

European Headache Federation (EHF) consensus on the definition of effective treatment of a migraine attack and of triptan failure
por: Sacco, Simona, et al.
Publicado: (2022)

Health technology assessment for the acute and preventive treatment of migraine: A position statement of the International Headache Society
por: Diener, Hans Christoph, et al.
Publicado: (2021)

A Comparison of the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study and American Migraine Prevalence and Prevention (AMPP) Study: Demographics and Headache‐Related Disability
por: Lipton, Richard B., et al.
Publicado: (2016)

European Headache Federation (EHF) critical reappraisal and meta-analysis of oral drugs in migraine prevention – part 3: topiramate
por: Raffaelli, Bianca, et al.
Publicado: (2023)

Prevention of migraine with monoclonal antibodies against CGRP or the CGRP receptor: Addition to the S1 guideline: Therapy of migraine attacks and prevention of migraine. Recommendations of the Germany Society of Neurology and the German Migraine and Headache Society
por: Diener, Hans-Christoph, et al.
Publicado: (2020)

European Headache Federation (EHF) critical re-appraisal and meta-analysis of oral drugs in migraine prevention—part 2: flunarizine
por: Deligianni, Christina I., et al.
Publicado: (2023)

Fremanezumab for the Preventive Treatment of Migraine: Subgroup Analysis by Number of Prior Preventive Treatments with Inadequate Response
por: Pazdera, Ladislav, et al.
Publicado: (2021)

European Headache Federation (EHF) critical re-appraisal and meta-analysis of oral drugs in migraine prevention—part 1: amitriptyline
por: Lampl, Christian, et al.
Publicado: (2023)

European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update
por: Sacco, Simona, et al.
Publicado: (2022)

Preventive migraine treatment with eptinezumab reduced acute headache medication and headache frequency to below diagnostic thresholds in patients with chronic migraine and medication‐overuse headache
por: Marmura, Michael J., et al.
Publicado: (2021)

Comorbid and co-occurring conditions in migraine and associated risk of increasing headache pain intensity and headache frequency: results of the migraine in America symptoms and treatment (MAST) study
por: Buse, Dawn C., et al.
Publicado: (2020)

Consistency vs. switching triptan treatment and headache-related disability: Results of the American migraine prevalence & prevention study
por: Buse, DC, et al.
Publicado: (2013)

Preventive Effect of Greater Occipital Nerve Block on Severity and Frequency of Migraine Headache
por: Kashipazha, Davood, et al.
Publicado: (2014)

Deterioration of headache impact and health-related quality of life in migraine patients after cessation of preventive treatment with CGRP(−receptor) antibodies
por: Terhart, Maria, et al.
Publicado: (2021)

Relevant factors for neurologists to define effectiveness of migraine preventive drugs and take decisions on treatment. My‐LIFE European Delphi survey
por: Pozo‐Rosich, Patricia, et al.
Publicado: (2021)

Shift in diagnostic classification of migraine after initiation of preventive treatment with eptinezumab: post hoc analysis of the PROMISE studies
por: Pozo-Rosich, Patricia, et al.
Publicado: (2022)

Impact of monthly headache days on anxiety, depression and disability in migraine patients: results from the Spanish Atlas
por: Irimia, P., et al.
Publicado: (2021)

Acute treatment optimization for migraine: results of the American migraine prevalence and prevention (AMPP) study
por: Lipton, RB, et al.
Publicado: (2013)

Fremanezumab for preventive treatment of migraine: Functional status on headache-free days
por: VanderPluym, Juliana, et al.
Publicado: (2018)

Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination
por: Raffaelli, Bianca, et al.
Publicado: (2019)

Perceived barriers to career progression in the headache field: A global web-based cross-sectional survey
por: de Boer, Irene, et al.
Publicado: (2022)

EHMTI-0270. Experience with onabotulinumtoxin type a in high-frequency episodic migraine
por: Pozo-Rosich, P, et al.
Publicado: (2014)

Headache as a Symptom of COVID-19: Narrative Review of 1-Year Research
por: Caronna, Edoardo, et al.
Publicado: (2021)

Vascular safety of erenumab for migraine prevention
por: Kudrow, David, et al.
Publicado: (2020)

The Effect of Psychiatric Comorbidities on Headache‐Related Disability in Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study
por: Lipton, Richard B., et al.
Publicado: (2020)

Systematic review of outcomes and endpoints in preventive migraine clinical trials
por: McGinley, James S., et al.
Publicado: (2021)

Anti-epileptic drugs in the preventive treatment of migraine headache: a brief review
por: Pini, Luigi-Alberto, et al.
Publicado: (2001)

Chronic migraine headache prevention with noninvasive vagus nerve stimulation: The EVENT study
por: Silberstein, Stephen D., et al.
Publicado: (2016)

In search of a gold standard patient-reported outcome measure to use in the evaluation and treatment-decision making in migraine prevention. A real-world evidence study
por: Alpuente, Alicia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9f3iq93ddfq1o8sn5fdba0gchd